vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes
24 juin 2024 16h05 HE
|
vTv Therapeutics Inc.
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed...
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
09 mai 2024 16h51 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for...
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
13 mars 2024 08h00 HE
|
vTv Therapeutics Inc.
Recently completed $51 million PIPE from healthcare-focused institutional investors and the JDRF T1D Fund.Company's first Phase 3 clinical trial of cadisegliatin (TTP399), an oral adjunctive...
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
04 mars 2024 08h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
01 mars 2024 08h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
28 févr. 2024 08h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
09 nov. 2023 16h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
08 nov. 2023 08h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
02 nov. 2023 08h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
01 nov. 2023 08h00 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an...